<DOC>
	<DOCNO>NCT02595060</DOCNO>
	<brief_summary>This trial evaluate efficacy safety inhale molgramostim ( rhGM-CSF ) 45 patient pneumonia associate acute respiratory distress syndrome ( ARDS ) . A third patient receive 150 mcg inhale molgramostim , another third 450 mcg remain third receive inhale placebo 3 day . The patient follow 28 day .</brief_summary>
	<brief_title>Granulocyte Macrophage-Colony Stimulating Factor ( GM-CSF ) Inhalation Improve Host Defense Pulmonary Barrier Restoration</brief_title>
	<detailed_description />
	<mesh_term>Molgramostim</mesh_term>
	<criteria>1 . Signed informed consent form patient legal representative accord local regulation 2 . Man woman 18 75 year age , inclusive 3 . Women postmenopausal 1 year woman childbearing potential period use highly efficient method contraception ( i.e . method le 1 % failure rate combine hormonal contraception , progesteroneonly hormonal contraception , intrauterine device , intrauterine hormonereleasing system , bilateral tube occlusion , vasectomized partner , sexual abstinence ) dose hospitalisation . Women must negative serum urine pregnancy test first dose study medication must lactate . 4 . Diagnosis pneumoniaassociated ARDS , underlie condition CommunityAcquired Pneumonia ( CAP ) HospitalAcquired Pneumonia ( HAP ) patient invasive ventilation upon diagnosis HAP . 5 . Diagnosis ARDS accord Berlin ARDS definition . 6 . Requirement positive pressure ventilation ( noninvasive via endotracheal tube ) 72 hour total inspiratory oxygen concentration ( FiO2 ) ≥ 50 % ( less additional ECMO therapy ) long 14 day 1 . Receiving vasopressor &gt; 100 µg/min 2 . History liver cirrhosis Child Pugh C , chronic hemodialysis ( severe pneumonia/ARDS ) , lung cancer 3 . Malignancy expect survival time le 6 month 4 . History list lung transplantation 5 . Highly immunosuppressive therapy antimalignant combination chemotherapy within 3 week prior first dose study drug 6 . Any antimalignant chemotherapy within 24 hour prior first dose study drug 7 . AIDS known history HIV infection 8 . Pregnancy 9 . Autoimmune thrombocytopenia , myelodysplastic syndrome &gt; 20 % marrow blast cell 10 . History presence hypersensitivity idiosyncratic reaction molgramostim relate compound ( i.e. , Growgen® , Leucomax® , Leukine™ , Topleucon™ ) 11 . Participation another clinical trial within 90 day prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>acute lung injury , molgramostim , GM-CSF , pneumonia , barrier restoration</keyword>
</DOC>